Abstract
The Middle East respiratory syndrome coronavirus (MERS-CoV) was first discovered in late 2012 and has gone on to cause over 1800 infections and 650 deaths. There are currently no approved therapeutics or vaccinations for MERS-CoV. The MERS-CoV spike (S) protein is responsible for receptor binding and virion entry to cells, is immunodominant and induces neutralizing antibodies in vivo, all of which, make the S protein an ideal target for anti-MERS-CoV vaccines. In this study, we demonstrate protection induced by vaccination with a recombinant MERS-CoV S nanoparticle vaccine and Matrix-M1 adjuvant combination in mice. The MERS-CoV S nanoparticle vaccine produced high titer anti-S neutralizing antibody and protected mice from MERS-CoV infection in vivo.
Keywords:
Coronavirus; MERS-CoV; Mouse model; Nanoparticle vaccine.
Copyright © 2017 Elsevier Ltd. All rights reserved.
Publication types
-
Research Support, N.I.H., Extramural
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adjuvants, Immunologic / administration & dosage
-
Animals
-
Antibodies, Neutralizing / blood
-
Antibodies, Viral / blood
-
Coronavirus Infections / prevention & control*
-
Disease Models, Animal
-
Mice, Inbred BALB C
-
Middle East Respiratory Syndrome Coronavirus / genetics
-
Middle East Respiratory Syndrome Coronavirus / immunology*
-
Spike Glycoprotein, Coronavirus / genetics
-
Spike Glycoprotein, Coronavirus / immunology*
-
Vaccines, Synthetic / administration & dosage
-
Vaccines, Synthetic / genetics
-
Vaccines, Synthetic / immunology
-
Vaccines, Virus-Like Particle / administration & dosage
-
Vaccines, Virus-Like Particle / genetics
-
Vaccines, Virus-Like Particle / immunology*
-
Viral Vaccines / administration & dosage
-
Viral Vaccines / genetics
-
Viral Vaccines / immunology*
Substances
-
Adjuvants, Immunologic
-
Antibodies, Neutralizing
-
Antibodies, Viral
-
Spike Glycoprotein, Coronavirus
-
Vaccines, Synthetic
-
Vaccines, Virus-Like Particle
-
Viral Vaccines